Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kitasato Daiichi Sankyo Vaccine to Construct New-type Flu Vaccine Manufacturing Facilities
September 5, 2011
- Mediscience Chairman Urae Appoints President to Consolidate Management
September 2, 2011
- Daiichi Sankyo Espha Asks Patent Office to Invalidate Combination Patents for Takeda’s Actos
September 2, 2011
- Companies Responsible for Disclosure of Pharmacoeconomic Data: Chairman Eiki of Bayer Yakuhin
September 2, 2011
- Ontario Canada Supports Roche Canada’s New Research Site
September 2, 2011
- Sanofi Pasteur Appoints New GM
September 2, 2011
- Sanofi-aventis Nichi-Iko Applies for Cefotax Based on Public Data
September 1, 2011
- Wakamoto: Sales Up 2.1% Resulting in Smaller Losses
August 3, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…